BioVaxys Presents PESCO Study Abstract at ASCO Annual Meeting
VANCOUVER, BC — April 27, 2026 — Leads & Copy — BioVaxys Technology Corp. announced the acceptance of an abstract related to the PESCO study for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 6, 2026.
The PESCO study is an investigator-initiated, open-label, non-randomized phase 1B/2 trial evaluating the safety and efficacy of BioVaxys’ MVP-S in combination with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer.
The ASCO Annual Meeting is a global oncology conference with over 44,000 expected attendees, including oncologists, researchers, and pharmaceutical professionals. It is recognized as a high-visibility event for clinical trials, research, and oncology innovation. Accepted ASCO abstracts are published online as a supplement to the Journal of Clinical Oncology (JCO).
MVP-S is BioVaxys’ investigational immunotherapeutic vaccine utilizing its lipid-based DPX™ delivery platform to stimulate T cell immune response to survivin epitopes restricted by 5 HLA class I haplotypes. It is in clinical development for ovarian, bladder and breast cancer, and for relapsed/refractory diffuse large B-cell lymphoma.
The abstract is entitled “Vaccine-induced immune responses, HLA genotyping, and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial)” and is led by Principal Investigator Amit Oza, MD, Head of the Division of Medical Oncology & Hematology, and Medical Director of University Health Network, Cancer Clinical Research Unit at Princess Margaret Cancer Centre (PMCC), Director of the Drug Development Program at the PMCC, and Professor of Medicine, University of Toronto.
The PESCO study was sponsored by University Health Network, with support from the Princess Margaret Cancer Centre, The Ontario Institute for Cancer Research, and Merck Sharp & Dohme.
Details for the poster presentation are as follows:
- Abstract Title: Vaccine-induced immune responses, HLA genotyping, and molecular profiling in patients with metastatic ovarian cancer (the PESCO trial).
- Session Type/Title: Poster Session – Gynecologic Cancer
- Poster Board: 266
- Date and Time: June 1, 2026, 9:00 AM-12:00 PM CDT
The BioVaxys DPX platform is an innovation in vaccine development. It presents antigens to the immune system using a non-systemic mechanism of action, forcing an active uptake of immune cells and delivery into the lymphatic nodes. The programming of immune cells happens in vivo, mimicking the natural function of the immune system. This mechanism allows for an active uptake of antigens into immune cells and lymph nodes for a sustained activation of the immune system.
Maveropepimut-S (MVP-S) is designed to target and eliminate survivin-expressing tumor cells. It is a DPX-based vaccine immunotherapy that induces a cytotoxic T-cell response. DPX is a non-aqueous, non-systemic, lipid-in-oil immune educating antigen delivering platform that is the foundation of BioVaxys’ oncology and infectious disease product pipeline. MVP-S is a DPX-based formulation of five peptides derived from survivin, a T helper peptide, and an innate immune stimulant. MVP-S has been shown to be well tolerated and has demonstrated activation of a targeted and sustained, survivin-specific anti-tumor immune response in multiple cancer indications.
Epithelial ovarian cancer (EOC) has poor survival due to late detection, high heterogenicity and development of resistance, highlighting the need for novel treatment strategies. The global Epithelial Ovarian Cancer market is projected to reach over USD $7.0 billion by 2033.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. The Company’s clinical stage oncology pipeline includes maveropepimut-S (MVP-S) in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum resistant Ovarian Cancer, and in phase 1 with neoadjuvant hormone therapy in HR(+) / HER2(-) stage II-III breast cancer. BioVaxys is also developing DPX™+SurMAGE, DPX™-RSV, DPX+rPA, and an DPX-mRNA formulation for rabies.
BioVaxys common shares are listed on the CSE under the stock symbol “BIOV”, trade on the Frankfurt Bourse (FSE: 5LB0) and in the U.S. on the OTC Markets (OTCQB: BVAXF).
Source: BioVaxys Technology Corp.
Share this story:
